| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
83,810,000 |
| Market
Cap: |
10.06(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.0375 - $6.3 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Mallinckrodt develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare disease in areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology, immunotherapy and neonatal respiratory critical care therapies, analgesics and gastrointestinal products. Co.'s reportable segments include: Specialty Brands, which markets branded pharmaceutical products for autoimmune and rare diseases; and Specialty Generics, which includes specialty generic drugs and active pharmaceutical ingredients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
308,000 |
403,000 |
403,000 |
439,133 |
| Total Buy Value |
$12,227,125 |
$15,790,625 |
$15,790,625 |
$16,096,924 |
| Total People Bought |
1 |
1 |
1 |
4 |
| Total Buy Transactions |
2 |
4 |
4 |
8 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schaefer Kathy A |
Sr. VP & Corp. Controller |
• – – |
2017-06-09 |
4 |
OE |
$31.23 |
$62,460 |
D/D |
2,000 |
17,151 |
|
- |
|
| Romano Steven J. |
Exec. VP & Chief Sci. Ofcr |
• – – |
2017-06-09 |
4 |
B |
$39.88 |
$39,881 |
D/D |
1,000 |
22,296 |
2.74 |
- |
|
| Lannum Coleman N Iii |
Sr. VP Investor Strategy & IRO |
• – – |
2017-06-09 |
4 |
B |
$39.77 |
$55,678 |
I/I |
1,400 |
3,000 |
1.99 |
- |
|
| Lannum Coleman N Iii |
Sr. VP Investor Strategy & IRO |
• – – |
2017-06-09 |
4 |
B |
$39.89 |
$61,825 |
D/D |
1,550 |
33,005 |
2.74 |
- |
|
| Trudeau Mark |
President and CEO |
• • – |
2017-06-09 |
4 |
B |
$40.17 |
$40,174 |
D/D |
1,000 |
264,053 |
2.81 |
- |
|
| Lloyd Ronald K. |
Exec. VP & Pres, Hospital |
• – – |
2017-06-09 |
4 |
B |
$41.26 |
$206,320 |
D/D |
5,000 |
17,967 |
2.74 |
- |
|
| Oneill Hugh M. |
Exec. VP & Pres, ARD |
• – – |
2017-06-08 |
4 |
B |
$40.24 |
$40,237 |
D/D |
1,000 |
31,009 |
2.74 |
- |
|
| Lannum Coleman N Iii |
Sr. VP Investor Strategy & IRO |
• – – |
2017-06-05 |
4 |
B |
$39.33 |
$19,665 |
D/D |
500 |
31,455 |
2.74 |
- |
|
| Lannum Coleman N Iii |
Sr. VP Investor Strategy & IRO |
• – – |
2017-06-02 |
4 |
B |
$42.89 |
$57,904 |
D/D |
1,350 |
30,955 |
2.74 |
- |
|
| Lannum Coleman N Iii |
Sr. VP Investor Strategy & IRO |
• – – |
2017-05-12 |
4 |
B |
$46.20 |
$90,912 |
D/D |
1,968 |
29,605 |
2.74 |
- |
|
| Hicks Michael-Bryant |
General Counsel |
• – – |
2017-04-01 |
4 |
D |
$44.57 |
$11,588 |
D/D |
(260) |
8,379 |
|
- |
|
| Scholz Frank |
EVP Glob Ops & Pres Spec Gen |
• – – |
2017-04-01 |
4 |
D |
$44.57 |
$104,561 |
D/D |
(2,346) |
41,951 |
|
- |
|
| Scholz Frank |
EVP Glob Ops & Pres Spec Gen |
• – – |
2017-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,588 |
44,297 |
|
- |
|
| Hicks Michael-Bryant |
General Counsel |
• – – |
2017-03-07 |
4 |
B |
$50.35 |
$14,602 |
D/D |
290 |
8,639 |
2.74 |
- |
|
| Sheehy Karen Patruno |
Sr. VP & Chief Compliance Off. |
• – – |
2017-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
582 |
4,835 |
|
- |
|
| Fischer Meredith B |
Chief Public Affairs Officer |
• – – |
2017-03-01 |
4 |
D |
$51.55 |
$7,681 |
D/D |
(149) |
27,418 |
|
- |
|
| Carroll J Martin |
Director |
– • – |
2017-03-01 |
4 |
D |
$51.55 |
$117,843 |
D/D |
(2,286) |
19,030 |
|
- |
|
| Carroll J Martin |
Director |
– • – |
2017-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,723 |
21,316 |
|
- |
|
| Gulyas Diane H. |
Director |
– • – |
2017-03-01 |
4 |
D |
$51.55 |
$117,843 |
D/D |
(2,286) |
18,896 |
|
- |
|
| Gulyas Diane H. |
Director |
– • – |
2017-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,723 |
21,182 |
|
- |
|
| Booth Melvin D |
Director |
– • – |
2017-03-01 |
4 |
D |
$51.55 |
$164,496 |
D/D |
(3,191) |
12,851 |
|
- |
|
| Booth Melvin D |
Director |
– • – |
2017-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,896 |
16,042 |
|
- |
|
| Thompson Virgil D |
Director |
– • – |
2017-03-01 |
4 |
D |
$51.55 |
$117,843 |
D/D |
(2,286) |
54,745 |
|
- |
|
| Reed Joann A |
Director |
– • – |
2017-03-01 |
4 |
D |
$51.55 |
$117,843 |
D/D |
(2,286) |
15,030 |
|
- |
|
| Reed Joann A |
Director |
– • – |
2017-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,723 |
17,316 |
|
- |
|
627 Records found
|
|
Page 13 of 26 |
|
|
